Cytomegalovirus (CMV) is a serious pathogen that leads to considerable illness and death in hematopoietic cell transplant (HCT) patients. The landscape for CMV prevention and treatment in this vulnerable population continues to evolve, with newer antiviral therapies offering efficacy and minimal side effects.
Optimal CMV management should include an individualized approach based on current guidelines, transplant conditioning regimens, treatment toxicities, and potential CMV drug resistance. Join our distinguished panel as they review state-of-the-art therapeutic considerations for managing CMV in HCT patients, including insights on a challenging clinical case from their practice.
Upon completion of this activity, participants should be better able to:
Director, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College, Cornell University
New York, NY
Professor and Chair
G. P. Bodey, Sr. Distinguished Professorship, Infectious Diseases
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, TX
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
